Heinz Gisslinger

Summary

Affiliation: Medical University of Vienna
Country: Austria

Publications

  1. ncbi request reprint Update on diagnosis and management of essential thrombocythemia
    Heinz Gisslinger
    Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University of Vienna, Vienna, Austria
    Semin Thromb Hemost 32:430-6. 2006
  2. pmc Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial
    Heinz Gisslinger
    Medical University of Vienna, Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Vienna, Austria
    Blood 121:1720-8. 2013
  3. pmc Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2
    Thorsten Klampfl
    CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
    PLoS ONE 8:e77819. 2013
  4. ncbi request reprint Plasma levels of P-selectin are determined by platelet turn-over and the P-selectin Thr715Pro polymorphism
    Simon Panzer
    Clinic for Blood Group Serology, Department of Internal Medicine I, Medical University of Vienna, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Thromb Res 121:573-9. 2008
  5. ncbi request reprint Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity
    Nina Worel
    Department of Bloodgroup Serology and Transfusion Medicine, Vienna Medical University, Vienna, Austria
    Wien Klin Wochenschr 118:49-53. 2006
  6. ncbi request reprint Continuous complete clinical and molecular remission in two patients with refractory lymphoid malignancies after autografting followed by allogeneic stem cell transplantation with reduced intensity conditioning
    Margit Mitterbauer
    Department of Medicine I, Bone Marrow Transplantation, University Hospital of Vienna, Vienna, Austria
    Br J Haematol 118:132-5. 2002
  7. doi request reprint High spontaneous granulocyte/macrophage-colony formation in patients with myelofibrosis
    Verena Hauer
    5th Department of Internal Medicine Oncology Hematology, Hospital Hietzing, Vienna, Austria
    Leuk Res 38:116-20. 2014
  8. doi request reprint High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone
    Daniel Heintel
    Department of Internal Medicine I, Center for Oncology and Haematology, Wilhelminenspital, Vienna, Austria
    Br J Haematol 161:695-700. 2013
  9. doi request reprint Clinical significance of genetic aberrations in secondary acute myeloid leukemia
    Jelena D Milosevic
    CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
    Am J Hematol 87:1010-6. 2012
  10. doi request reprint Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients
    Veronika Buxhofer-Ausch
    Division of Hematology and Blood Coagulation, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria
    Am J Hematol 87:669-72. 2012

Detail Information

Publications28

  1. ncbi request reprint Update on diagnosis and management of essential thrombocythemia
    Heinz Gisslinger
    Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University of Vienna, Vienna, Austria
    Semin Thromb Hemost 32:430-6. 2006
    ..The combination of anagrelide with acetylsalicylic acid may be contraindicated in patients with a history of bleeding...
  2. pmc Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial
    Heinz Gisslinger
    Medical University of Vienna, Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Vienna, Austria
    Blood 121:1720-8. 2013
    ..This trial was registered at http://www.clinicaltrials.gov as #NCT01065038...
  3. pmc Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2
    Thorsten Klampfl
    CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
    PLoS ONE 8:e77819. 2013
    ..Our chromosome-centered analysis indicates that chromosome 11 contains a number of tumor suppressor genes and that the role of this chromosome in myeloid malignancies is more complex than previously recognized. ..
  4. ncbi request reprint Plasma levels of P-selectin are determined by platelet turn-over and the P-selectin Thr715Pro polymorphism
    Simon Panzer
    Clinic for Blood Group Serology, Department of Internal Medicine I, Medical University of Vienna, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Thromb Res 121:573-9. 2008
    ..Plasma levels of soluble P-selectin (sP-selectin) are often used to demonstrate platelet activation...
  5. ncbi request reprint Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity
    Nina Worel
    Department of Bloodgroup Serology and Transfusion Medicine, Vienna Medical University, Vienna, Austria
    Wien Klin Wochenschr 118:49-53. 2006
    ....
  6. ncbi request reprint Continuous complete clinical and molecular remission in two patients with refractory lymphoid malignancies after autografting followed by allogeneic stem cell transplantation with reduced intensity conditioning
    Margit Mitterbauer
    Department of Medicine I, Bone Marrow Transplantation, University Hospital of Vienna, Vienna, Austria
    Br J Haematol 118:132-5. 2002
    ..Both patients achieved sustained complete haematological and molecular remission of the immunoglobulin kappa light chain (Igkappa) rearrangement and are alive and well 17 and 16 months after SCT respectively...
  7. doi request reprint High spontaneous granulocyte/macrophage-colony formation in patients with myelofibrosis
    Verena Hauer
    5th Department of Internal Medicine Oncology Hematology, Hospital Hietzing, Vienna, Austria
    Leuk Res 38:116-20. 2014
    ..Spontaneous CFU-GM growth >100/10(5) PBMNC predicted shorter survival. Constitutive release of GM-CSF seems to contribute to proliferation of MF cells in vitro and possibly in vivo. ..
  8. doi request reprint High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone
    Daniel Heintel
    Department of Internal Medicine I, Center for Oncology and Haematology, Wilhelminenspital, Vienna, Austria
    Br J Haematol 161:695-700. 2013
    ..CRBN expression is closely associated with IRF4, which is an important target of IMiD therapy...
  9. doi request reprint Clinical significance of genetic aberrations in secondary acute myeloid leukemia
    Jelena D Milosevic
    CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
    Am J Hematol 87:1010-6. 2012
    ..Somatic mutations in TP53 are the only independent adverse prognostic factor in sAML. Patients with dnAML and complex karyotype show genetic features associated with sAML and myeloproliferative neoplasms...
  10. doi request reprint Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients
    Veronika Buxhofer-Ausch
    Division of Hematology and Blood Coagulation, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria
    Am J Hematol 87:669-72. 2012
    ..027, HR 0.19). Moreover, a lower hemoglobin level was associated with an increased risk for venous thrombosis (P = 0.007, HR 0.59). Our data indicate that leukocytosis is a prominent risk factor for thrombosis in early/prefibrotic MF...
  11. ncbi request reprint Therapy strategies for multiple myeloma: current status
    Heinz Gisslinger
    Division of Haematology and Blood Coagulation, Department of Internal Medicine I, University of Vienna, Vienna, Austria
    Wien Klin Wochenschr 115:451-61. 2003
    ..New generations of bisphosphonates show potent antitumor activity, again emphasising the importance of targeting the microenvironment of the plasma-cell clone...
  12. ncbi request reprint Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma
    Heinz Ludwig
    Department of Medicine and Medical Oncology, Wilhelminenspital, Vienna, Austria
    Br J Haematol 131:329-37. 2005
    ..In conclusion, continuing prednisolone treatment during the entire duration of the induction phase with VMCP-IFN-alpha 2b did not improve outcome...
  13. doi request reprint Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma
    Heinz Ludwig
    Department of Medicine I, Wilhelminenspital Vienna, Vienna, Austria
    Blood 113:3435-42. 2009
    ..5 vs 49.4 months; P= .024). Toxicity was higher with TD, particularly in patients older than 75 years with poor performance status. The study was registered at ClinicalTrials.gov as NCT00205751...
  14. ncbi request reprint Circulating hematopoietic progenitor cells predict survival in patients with myelofibrosis with myeloid metaplasia
    Verena Sagaster
    Department of Internal Medicine I, Division of Hematology, University of Vienna, Vienna, Austria
    Haematologica 88:1204-12. 2003
    ..The levels of circulating hematopoietic progenitor cells are often increased in myelofibrosis with myeloid metaplasia (MMM). The prognostic relevance of this phenomenon is largely unknown...
  15. ncbi request reprint Age and hemoglobin level emerge as most important clinical prognostic parameters in patients with osteomyelofibrosis: introduction of a simplified prognostic score
    Kathrin Strasser-Weippl
    First Medical Department with Medical Oncology, Wilhelminen Hospital, Vienna, Austria
    Leuk Lymphoma 47:441-50. 2006
    ..This is in contrast to previous prognostic scores, in which the poor prognosis group was often very small and/or could not be consistently differentiated from patients with an intermediate prognosis...
  16. ncbi request reprint High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience
    Alexandra Bohm
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Leuk Res 29:609-15. 2005
    ..The median overall- and disease-free survival were 19.3 and 11.3 months, respectively. The best outcome was seen in patients aged <40 years. These results confirm that HiDAC is a safe and effective consolidation in AML...
  17. ncbi request reprint Elevated plasma osteoprotegerin levels are associated with venous thrombosis and bleeding in patients with polycythemia vera
    Mathias Kees
    Medical University Vienna, Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Thromb Haemost 93:70-5. 2005
    ..017). This is the first report that links the occurrence of venous thrombosis or bleeding to elevated OPG levels...
  18. ncbi request reprint Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile
    Michael Steurer
    Division of Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria
    Cancer 101:2239-46. 2004
    ..In the current study, the authors evaluated the efficacy and tolerability of anagrelide in thrombocytosis associated with myeloproliferative disorders...
  19. ncbi request reprint Oral anticoagulants as secondary prophylaxis of thrombosis in patients with polycythemia vera: a retrospective analysis of 15 patients
    Thomas Bachleitner-Hofmann
    Department of Surgery, University of Vienna General Hospital, Austria
    Thromb Res 112:229-32. 2003
    ..0. In our opinion, a prospective clinical trial similar to the recently performed ECLAP study would be needed to more thoroughly elucidate the efficacy of OA in the secondary prophylaxis of thrombosis in PV...
  20. ncbi request reprint Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia
    Marco Ruggeri
    Department of Hematology, S Bortolo Hospital, Vicenza, Italy
    Am J Hematol 71:1-6. 2002
    ..FV Leiden mutation is a risk factor for VTE before and at time of diagnosis and for VTE recurrences. Screening for FV Leiden may be considered to identify PV and ET patients at higher risk of recurrences...
  21. ncbi request reprint Imatinib mesylate inhibits autonomous erythropoiesis in patients with polycythemia vera in vitro
    Leopold Oehler
    Internal Medicine I, Division of Hematology, University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Blood 102:2240-2. 2003
    ..The profound effect of imatinib mesylate on autonomous erythropoiesis suggests the involvement of an as yet unidentified kinase in the pathogenesis of PV and should provide the rationale for a forthcoming clinical trial...
  22. ncbi request reprint Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study
    Guido Finazzi
    Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy
    Blood 105:2664-70. 2005
    ..84-16.25; P = .0023), but not to hydroxyurea (HU) alone (HR, 0.86; 95% CI, 0.26-2.88; P = .8021), had an independent role in producing an excess risk for progression to AML/MDS compared with treatment with phlebotomy or interferon...
  23. ncbi request reprint Mutation of the prothrombin gene and thrombotic events in patients with polycythemia vera or essential thrombocythemia: a cohort study
    Heinz Gisslinger
    Haematologica 90:408-10. 2005
    ..The rate for venous thrombotic events was 14.7/100 patient-years in patients with the prothrombin mutation compared to 0.8 in patients without the mutation (rate ratio 17.5)...
  24. ncbi request reprint Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel
    Ayalew Tefferi
    Mayo Clinic, Rochester, MN 55905, USA
    Blood 110:1092-7. 2007
    ....
  25. ncbi request reprint Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and
    Ruben A Mesa
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 31:737-40. 2007
    ....
  26. ncbi request reprint Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study
    Christian Langer
    Department of Medicine III, University of Ulm, Germany
    Haematologica 90:1333-8. 2005
    ..We evaluated the efficacy and toxicity of pegylated interferon in high-risk essential thrombocythemia in a phase II trial...
  27. ncbi request reprint Efficacy and safety of low-dose aspirin in polycythemia vera
    Raffaele Landolfi
    Catholic University School of Medicine, Rome, Italy
    N Engl J Med 350:114-24. 2004
    ..The use of aspirin for the prevention of thrombotic complications in polycythemia vera is controversial...
  28. ncbi request reprint Bone metabolism during interferon-alpha treatment of essential thrombocythemia
    Rajko Kusec
    Institute of Clinical Chemistry and Department of Medicine, University Hospital Merkur, Zagreb, Croatia
    Wien Klin Wochenschr 116:37-41. 2004
    ..Correlations indicated modulation of bone metabolism, i.e. remodeling with suppression of resorption, as a consequence of therapy with IFN-alpha...